-
CSBTA Pharmacokinetics in MASH Mice: Study Insights
2026-09-07
The 2025 Biomedicine & Pharmacotherapy study integrates plasma pharmacokinetics, tissue distribution, cellular transport, microsomal metabolism, and regulatory protein expression to explain how MASH alters exposure to Corydalis saxicola Bunting total alkaloids. Its findings show that disease state and repeated dosing can increase systemic and hepatic accumulation, highlighting the importance of pathology-aware dose design in MASLD/MASH research.
-
RapaLink-1: Third-Generation mTOR Inhibitor
2026-09-07
RapaLink-1 is a third-generation mTOR inhibitor that combines FKBP12 engagement with dual-pocket mTOR binding to address resistance-associated signaling. Product data report potent mTORC1 inhibition, glioma cell growth inhibition, and tumor regression in an intracranial U87MG xenograft model.
-
Recombinant Annexin V for Apoptosis Detection
2026-09-05
Brumatti, Sheridan, and Martin established a practical bacterial-expression and purification workflow for soluble, polyhistidine-tagged Annexin V, followed by FITC labeling for flow cytometry and fluorescence microscopy. The study made phosphatidylserine externalization easier to measure reproducibly, while also clarifying why calcium-dependent membrane binding is powerful but not by itself a complete definition of apoptotic cell death.
-
BH3 Mimetics Target Senescent TP53-Wild-Type Breast Cancer
2026-09-04
The reference study shows that chemotherapy-induced senescence can leave TP53-wild-type breast cancer cells alive and capable of driving relapse. By combining BH3 mimetics with chemotherapy, the authors selectively eliminated a senescent tumor-cell subset, improved tumor regression, and extended survival in a mouse model, while revealing BCL-XL, MCL1, and NOXA as important determinants of response.
-
AT13387: Reliable Hsp90 Inhibition Assays
2026-09-04
A scenario-based guide to using AT13387 (SKU A4056) in cell viability, proliferation, and cytotoxicity workflows. It explains mechanism, solvent compatibility, dose-response planning, interpretation of apoptosis-associated readouts, and practical criteria for selecting a reliable Hsp90 inhibitor.
-
D-Luciferin for Translational Glioblastoma Imaging
2026-09-03
D-Luciferin is more than a light-generating reagent: it is a strategic bridge between engineered biology, intracellular ATP quantification, and longitudinal tumor burden assessment. This article interprets the cRGD-PEG-siEGFR glioblastoma study through a translational imaging lens, clarifying what firefly luciferase readouts can reveal, where they require orthogonal validation, and how researchers can design more decision-ready workflows.
-
1-Myristoylglycerophosphocholine: From Lipid to Mechanism
2026-09-03
A translational framework for using 1-myristoylglycerophosphocholine and 14:0 Lyso-PC to connect lipid metabolism, fibroblast activation, and smooth muscle biology while preserving species-level rigor.
-
HNRNPU K181 Lactylation Reprograms Serine Metabolism
2026-09-02
The reference study identifies HNRNPU lysine 181 lactylation as a non-histone regulatory event that connects lactate accumulation with PHGDH expression, serine biosynthesis, and cervical cancer growth. Its evidence suggests that a lactylation–acetylation switch controls HNRNPU stability and RNA-binding activity, while pharmacological disruption of this axis provides a potential strategy for testing metabolic vulnerabilities.
-
Ratiometric Imaging of Amyloid-β Fibrils with Ru(II)
2026-09-02
The reference study introduces dual-emissive tris-heteroleptic Ru(II) complexes that detect amyloid-β aggregation through an internal fluorescence/phosphorescence ratio. Complex 2 extends ratiometric sensing from bulk emission measurements to confocal imaging, while docking and computational analyses help explain its stronger interaction with Aβ40 fibrils.
-
Fluorouracil: A Clone-Aware Research Framework
2026-09-01
Fluorouracil and 5-Fluorouracil are powerful tools for studying thymidylate synthase blockade and tumor evolution. This article presents a clone-aware framework that connects molecular response, assay design, and metastatic heterogeneity in colorectal cancer research.
-
Amyloid Beta-Peptide (1-40): Microglia Workflows
2026-09-01
Build state-aware assays with Amyloid Beta-Peptide (1-40) (human) for aggregation, microglial signaling, and neurotoxicity studies. This practical guide connects peptide handling to the reference study’s monomer-sensitive APP/G-protein findings while adding controls and troubleshooting steps for reproducible Alzheimer’s disease research.
-
3-Aminobenzamide in PARP Stress Assays
2026-08-31
3-Aminobenzamide (PARP-IN-1) provides a practical pharmacologic switch for studying PARP activity across oxidative-stress, vascular, renal, and innate-immunity models. Its nanomolar cellular potency, broad solubility profile, and compatibility with orthogonal functional readouts support dose-controlled workflows rather than single-endpoint screening.
-
PA-824: Bicyclic Nitroimidazole in TB Research
2026-08-31
PA-824 is a bicyclic nitroimidazole derivative and tuberculosis research compound with activity against replicating and non-replicating Mycobacterium tuberculosis. Its reported profile combines ketomycolate biosynthesis inhibition with enzymatic nitro-reduction and intracellular nitric oxide release, while recent pretomanid research links activity to inhibition of both terminal respiratory branches.
-
Reparixin: Testing the IL-8–CXCR1/2 Axis
2026-08-30
A recent study links methicillin-resistant Staphylococcus aureus extracellular vesicles to IL-8–CXCR1 signaling and oral squamous cell carcinoma growth. This thought-leadership framework explains how Reparixin, a CXCR1/2 inhibitor, can help translational researchers separate receptor-level causality from broader inflammatory and tumor-promoting effects.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody
2026-08-29
K1223 provides an HRP-labeled, affinity-purified secondary antibody for detecting rabbit IgG primary antibodies in Western blotting, ELISA, IHC, and immunocytochemistry. It should be used for research assay development and validation, not as a diagnostic reagent or as a universal secondary antibody for non-rabbit immunoglobulins.